{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:39:23Z","timestamp":1793317163029,"version":"4.5.0"},"reference-count":229,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biliary tract carcinoma (BTC) is relatively rare and comprises a spectrum of invasive tumors arising from the biliary tree. The prognosis is extremely poor. The incidence of BTC is relatively high in Asian countries, and a high number of cases are diagnosed annually in China owing to the large population. Therefore, it is necessary to clarify the epidemiology and high-risk factors for BTC in China. The signs associated with BTC are complex, often require collaborative treatment from surgeons, endoscopists, oncologists, and radiation therapists. Thus, it is necessary to develop a comprehensive Chinese guideline for BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This clinical practice guideline (CPG) was developed following the process recommended by the World Health Organization. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty of evidence and make recommendations. The full CPG report was reviewed by external guideline methodologists and clinicians with no direct involvement in the development of this CPG. Two guideline reporting checklists have been adhered to: Appraisal of Guidelines for Research and Evaluation (AGREE) and Reporting Items for practice Guidelines in Healthcare (RIGHT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The guideline development group, which comprised 85 multidisciplinary clinical experts across China. After a controversies conference, 17 clinical questions concerning the prevention, diagnosis, and treatment of BTC were proposed. Additionally, detailed descriptions of the surgical principles, perioperative management, chemotherapy, immunotherapy, targeted therapy, radiotherapy, and endoscopic management were proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The guideline development group created a comprehensive Chinese guideline for the diagnosis and treatment of BTC, covering various aspects of epidemiology, diagnosis, and treatment. The 17 clinical questions have important reference value for the management of BTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003258","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:09Z","timestamp":1725580809000},"page":"2272-2293","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers"],"prefix":"10.1097","volume":"137","author":[{"given":"Xu\u2019an","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Biliary and Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine; State Key Laboratory of Systems Medicine for Cancers, Shanghai Cancer Institute; Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation, Shanghai 200127, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongrui","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningli","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, the First Medical Center, Chinese People\u2019s Liberation Army General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiong","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqiang","family":"Linghu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, the First Medical Center, Chinese People\u2019s Liberation Army General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute; Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biliary and Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine; State Key Laboratory of Systems Medicine for Cancers, Shanghai Cancer Institute; Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation, Shanghai 200127, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Society of Hepato-pancreato-biliary Surgery of Chinese Research Hospital Association, Society of Digestive Endoscopy of the Chinese Medical Association, Chinese Medical Journal Clinical Practice Guideline Collaborative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"i1152","DOI":"10.1136\/bmj.i1152","article-title":"The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines","volume":"352","author":"Brouwers","year":"2016","journal-title":"BMJ"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.zefq.2017.10.008","article-title":"A reporting tool for practice guidelines in health care: the RIGHT statement","volume":"127-128","author":"Chen","year":"2017","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11606-019-05508-3","article-title":"A Comparison of AGREE and RIGHT: which Clinical Practice Guideline Reporting Checklist Should Be Followed by Guideline Developers?","volume":"35","author":"Yao","year":"2020","journal-title":"J Gen Intern Med"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement","volume":"166","author":"Chen","year":"2017","journal-title":"Ann Intern Med"},{"key":"R9-20250602","first-page":"1124","article-title":"Progress of genomic mutation spectrum in biliary tract malignant tumors (in Chinese)","volume":"61","author":"Qiu","year":"2023","journal-title":"Chin J Surg"},{"key":"R10-20250602","first-page":"156","article-title":"Advance in immunotherapy on biliary tract cancers (in Chinese)","volume":"59","author":"Liu","year":"2021","journal-title":"Chin J Surg"},{"issue":"Suppl 1","key":"R11-20250602","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41395-018-0207-4","article-title":"Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis","volume":"113","author":"Petrick","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jhbp.62","article-title":"Roles of liver fluke infection as risk factor for cholangiocarcinoma","volume":"21","author":"Sithithaworn","year":"2014","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41416-020-0835-5","article-title":"Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the\u00a0UK Biobank","volume":"123","author":"Petrick","year":"2020","journal-title":"Br J Cancer"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J Hepatol"},{"key":"R17-20250602","first-page":"697","article-title":"Analysis of treatment modalities and prognosis of patients with gallbladder cancer in China from 2010 to 2017 (in Chinese)","volume":"58","author":"Ren","year":"2020","journal-title":"Chin J Surg"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.22756","article-title":"Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China","volume":"121","author":"Hsing","year":"2007","journal-title":"Int J Cancer"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.scib.2022.01.011","article-title":"Long-term exposure to genistein inhibits the proliferation of gallbladder cancer by downregulating the MCM complex","volume":"67","author":"Geng","year":"2022","journal-title":"Sci Bull (Beijing)"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/01.pas.0000213435.99492.8a","article-title":"Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence","volume":"31","author":"Lewis","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/cam4.915","article-title":"Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis","volume":"5","author":"Koshiol","year":"2016","journal-title":"Cancer Med"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2468-1253(17)30002-X","article-title":"Pancreaticobiliary maljunction and congenital biliary dilatation","volume":"2","author":"Kamisawa","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"43669","DOI":"10.18632\/oncotarget.9664","article-title":"The association between BMI and gallbladder cancer risk: a meta-analysis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R26-20250602","first-page":"1159","article-title":"Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia","volume":"11","author":"Shin","year":"2010","journal-title":"Asian Pac J Cancer Prev"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-015-1475-7","article-title":"Cohort profile: cholangiocarcinoma screening and care program (CASCAP)","volume":"15","author":"Khuntikeo","year":"2015","journal-title":"BMC Cancer"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-2-10","article-title":"Worldwide trends in mortality from biliary tract malignancies","volume":"2","author":"Patel","year":"2002","journal-title":"BMC Cancer"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/89.15.1132","article-title":"Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer","volume":"89","author":"Zatonski","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"216184","DOI":"10.1016\/j.canlet.2023.216184","article-title":"YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer","volume":"563","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"R33-20250602","first-page":"1352","article-title":"Nicotinamide N -methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2021.04.007","article-title":"SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition","volume":"510","author":"Liu","year":"2021","journal-title":"Cancer Lett"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11684-023-1008-8","article-title":"Topological reorganization and functional alteration of distinct genomic components in gallbladder cancer","volume":"18","author":"Li","year":"2024","journal-title":"Front Med"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","article-title":"Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis","volume":"68","author":"Li","year":"2019","journal-title":"Gut"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"(18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis","volume":"71","author":"Lamarca","year":"2019","journal-title":"J Hepatol"},{"key":"R39-20250602","first-page":"249","article-title":"Attach importance to the standardized diagnosis and treatment of gallbladder carcinoma (in Chinese)","volume":"59","author":"Liu","year":"2021","journal-title":"Chin J Surg"},{"key":"R40-20250602","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.hpb.2021.05.005","article-title":"Consensus guidelines on the role of cholangioscopy to diagnose indeterminate biliary stricture","volume":"24","author":"Angsuwatcharakon","year":"2022","journal-title":"HPB (Oxford)"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s00464-021-08571-2","article-title":"Diagnostic performance of digital and video cholangioscopes in patients with suspected malignant biliary strictures: a systematic review and meta-analysis","volume":"36","author":"Kulpatcharapong","year":"2022","journal-title":"Surg Endosc"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.gie.2019.11.025","article-title":"Digital single-operator peroral cholangioscopy-guided biopsy sampling versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized, multicenter trial (with video)","volume":"91","author":"Gerges","year":"2020","journal-title":"Gastrointest Endosc"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s10620-020-06335-x","article-title":"Combination of ERCP-Based Modalities Increases Diagnostic Yield for Biliary Strictures","volume":"66","author":"Han","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.gie.2011.09.020","article-title":"Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study","volume":"75","author":"Draganov","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"R45-20250602","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.gie.2005.04.032","article-title":"Diagnostic utility of peroral cholangioscopy for various bile-duct lesions","volume":"62","author":"Fukuda","year":"2005","journal-title":"Gastrointest Endosc"},{"key":"R46-20250602","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1016\/S0016-5085(17)31282-9","article-title":"Comparison of Accuracy of Simultaneous Cholangioscopic Biopsies and Fluorescence in-Situ Hybridization in Biliary Strictures","volume":"152","author":"Kokoy-Mondragon","year":"2017","journal-title":"Gastroenterology"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.gie.2023.06.005","article-title":"American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology: summary and recommendations","volume":"98","author":"Fujii-Lau","year":"2023","journal-title":"Gastrointest Endosc"},{"key":"R48-20250602","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/a-1083-6105","article-title":"Diagnostic performance of different cholangioscopes in patients with biliary strictures: a systematic review","volume":"52","author":"Kulpatcharapong","year":"2020","journal-title":"Endoscopy"},{"key":"R49-20250602","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.dld.2022.04.019","article-title":"Digital single-operator cholangioscopy in diagnostic and therapeutic bilio-pancreatic diseases: A prospective, multicenter study","volume":"54","author":"Fugazza","year":"2022","journal-title":"Dig Liver Dis"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.gie.2016.08.020","article-title":"Cost utility of ERCP-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis","volume":"85","author":"Njei","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.3748\/wjg.v21.i15.4722","article-title":"Per oral cholangiopancreatoscopy in pancreatico biliary diseases--expert consensus statements","volume":"21","author":"Ramchandani","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/apt.14811","article-title":"Review article: Asia-Pacific consensus recommendations on endoscopic tissue acquisition for biliary strictures","volume":"48","author":"Sun","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R53-20250602","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1055\/a-1611-5091","article-title":"Endoscopic tissue sampling - Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"53","author":"Pouw","year":"2021","journal-title":"Endoscopy"},{"key":"R54-20250602","first-page":"772","article-title":"Chinese guidelines for ERCP (2018) (in Chinese)","volume":"57","year":"2018","journal-title":"Chin J Intern Med"},{"key":"R55-20250602","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/eus.eus_24_19","article-title":"The incremental benefit of EUS for the identification of malignancy in indeterminate extrahepatic biliary strictures: A systematic review and meta-analysis","volume":"8","author":"Chiang","year":"2019","journal-title":"Endosc Ultrasound"},{"key":"R56-20250602","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1007\/s10620-021-07138-4","article-title":"Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis","volume":"67","author":"Yoon","year":"2022","journal-title":"Dig Dis Sci"},{"key":"R57-20250602","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/a-0645-1395","article-title":"Tissue acquisition for diagnosis of biliary strictures using peroral cholangioscopy or endoscopic ultrasound-guided fine-needle aspiration","volume":"51","author":"Lee","year":"2019","journal-title":"Endoscopy"},{"key":"R58-20250602","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cam4.1034","article-title":"Diagnostic approach using ERCP-guided transpapillary forceps biopsy or EUS-guided fine-needle aspiration biopsy according to the nature of stricture segment for patients with suspected malignant biliary stricture","volume":"6","author":"Lee","year":"2017","journal-title":"Cancer Med"},{"key":"R59-20250602","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/hep.31077","article-title":"Endoscopic Ultrasound\/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma","volume":"72","author":"Malikowski","year":"2020","journal-title":"Hepatology"},{"key":"R60-20250602","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1055\/a-2005-3679","article-title":"Endoscopic ultrasound in patients with resectable perihilar cholangiocarcinoma: impact on clinical decision-making","volume":"11","author":"de Jong","year":"2023","journal-title":"Endosc Int Open"},{"key":"R61-20250602","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"R62-20250602","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0043-109021","article-title":"Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017","volume":"49","author":"Dumonceau","year":"2017","journal-title":"Endoscopy"},{"key":"R63-20250602","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2015.08.046","article-title":"An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples","volume":"149","author":"Barr Fritcher","year":"2015","journal-title":"Gastroenterology"},{"key":"R64-20250602","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"R65-20250602","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"key":"R66-20250602","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"R67-20250602","first-page":"9","article-title":"The value of caudate lobectomy in hilar cholangiocarcinoma treatment A meta-analysis","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine"},{"key":"R68-20250602","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ejso.2020.01.023","article-title":"A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma","volume":"46","author":"Birgin","year":"2020","journal-title":"EJSO"},{"key":"R69-20250602","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1245\/s10434-022-11990-7","article-title":"Does Caudate Resection Improve Outcomes of Patients Undergoing Curative Resection for Perihilar Cholangiocarcinoma? A Systematic Review and Meta-Analysis","volume":"29","author":"Gilbert","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R70-20250602","first-page":"8","article-title":"Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R71-20250602","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1007\/s11605-014-2667-1","article-title":"Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review","volume":"18","author":"Amini","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"R72-20250602","first-page":"339","article-title":"Effect of abdominal lymphadenectomy on prognosis of intrahepatic cholangiocarcinoma: a systematic review and Meta analysis (in Chinese)","volume":"15","author":"Zeng","year":"2016","journal-title":"Chin J Digest Surg"},{"key":"R73-20250602","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma Systematic Review and Meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"R74-20250602","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.hpb.2018.12.011","article-title":"Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis","volume":"21","author":"Zhou","year":"2019","journal-title":"HPB"},{"key":"R75-20250602","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4240\/wjgs.v13.i2.176","article-title":"Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: Results from 24 hospitals in China","volume":"13","author":"Ren","year":"2021","journal-title":"World J Gastrointest Surg"},{"key":"R76-20250602","first-page":"265","article-title":"Diagnosis and treatment for unexpected gallbladder carcinoma (a retrospective study of 45 cases) (in Chinese)","volume":"57","author":"Wu","year":"2019","journal-title":"Chin J Surg"},{"key":"R77-20250602","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eclinm.2023.101951","article-title":"Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study","volume":"59","author":"Balakrishnan","year":"2023","journal-title":"Eclinicalmedicine"},{"key":"R78-20250602","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/bjs.11618","article-title":"Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: an international multicentre study","volume":"107","author":"Kwon","year":"2020","journal-title":"Br J Surg"},{"key":"R79-20250602","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.surg.2020.12.039","article-title":"Hepatectomy strategy for T2 gallbladder cancer between segment IVb and V resection and wedge resection: A propensity score-matched","volume":"169","author":"Chen","year":"2021","journal-title":"Surgery"},{"key":"R80-20250602","first-page":"7","article-title":"Comparative analysis of postoperative curative effect of liver wedge resection and liver IVb","volume":"10","author":"Wang","year":"2023","journal-title":"Front Surg"},{"key":"R81-20250602","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00534-012-0584-9","article-title":"Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma: analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery","volume":"20","author":"Horiguchi","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R82-20250602","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s11605-023-05698-6","article-title":"Surgical and Oncological Outcomes of Wedge Resection Versus Segment 4b+5 Resection for T2 and T3 Gallbladder Cancer: a Meta-Analysis","volume":"27","author":"Matsui","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"R83-20250602","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.ejso.2019.03.033","article-title":"Defining enhanced recovery after resection of peri-hilar cholangiocarcinoma","volume":"45","author":"Quinn","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"R84-20250602","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1016\/j.hpb.2018.06.2734","article-title":"Efficacy analysis of using enhanced recovery after surgery in perioperative period of radical surgery for cholangiocarcinoma","volume":"20","author":"Shao","year":"2018","journal-title":"HPB"},{"key":"R85-20250602","first-page":"CD011382","article-title":"Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery","volume":"2","author":"Bond-Smith","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R86-20250602","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12957-016-0933-2","article-title":"Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review","volume":"14","author":"Moole","year":"2016","journal-title":"World J Surg Oncol"},{"key":"R87-20250602","doi-asserted-by":"crossref","DOI":"10.1080\/13651820801992666","article-title":"Preoperative biliary drainage before resection for cholangiocarcinoma (Pro)","volume":"10","author":"Nimura","year":"2008","journal-title":"HPB"},{"key":"R88-20250602","first-page":"CD005444","article-title":"Pre-operative biliary drainage for obstructive jaundice","volume":"3","author":"Wang","year":"2012","journal-title":"Cochrane database of systematic reviews (Online)"},{"key":"R89-20250602","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archsurg.135.3.302","article-title":"Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage","volume":"135","author":"Cherqui","year":"2000","journal-title":"Arch Surg"},{"key":"R90-20250602","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejso.2017.04.001","article-title":"Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis","volume":"43","author":"Celotti","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R91-20250602","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","article-title":"Overview of current targeted therapy in gallbladder cancer","volume":"5","author":"Song","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R92-20250602","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1245\/s10434-021-11206-4","article-title":"Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma","volume":"29","author":"Matsuyama","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R93-20250602","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-015-2908-3","article-title":"Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer","volume":"76","author":"Kobayashi","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"R94-20250602","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s00268-018-4558-1","article-title":"Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma","volume":"42","author":"Sumiyoshi","year":"2018","journal-title":"World J Surg"},{"key":"R95-20250602","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1245\/s10434-016-5197-0","article-title":"Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm","volume":"23","author":"Engineer","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R96-20250602","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","article-title":"Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma","volume":"221","author":"Sutton","year":"2021","journal-title":"Am J Surg"},{"key":"R97-20250602","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"Br J Surg"},{"key":"R98-20250602","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2016.12.058","article-title":"Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes","volume":"224","author":"Creasy","year":"2017","journal-title":"J Am Coll Surg"},{"key":"R99-20250602","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hpb.2018.03.008","article-title":"Outcome of neoadjuvant chemotherapy in \u201clocally advanced\/borderline resectable\u201d gallbladder cancer: the need to define indications","volume":"20","author":"Chaudhari","year":"2018","journal-title":"HPB (Oxford)"},{"key":"R100-20250602","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-023-02754-y","article-title":"Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"R101-20250602","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejso.2018.08.020","article-title":"The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review","volume":"45","author":"Hakeem","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"R102-20250602","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"R103-20250602","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"R104-20250602","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"R105-20250602","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"R106-20250602","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"R107-20250602","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"R108-20250602","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","article-title":"A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group","volume":"270","author":"Kobayashi","year":"2019","journal-title":"Ann Surg"},{"key":"R109-20250602","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1245\/s10434-020-08355-3","article-title":"Phase 2 Trial of Adjuvant Chemotherapy With S\u2009-\u20091 for Node-Positive Biliary Tract Cancer (N-SOG 09)","volume":"27","author":"Seita","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R110-20250602","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"R111-20250602","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","article-title":"Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study","volume":"18","author":"Siebenh\u00fcner","year":"2018","journal-title":"BMC Cancer"},{"key":"R112-20250602","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00534-011-0437-y","article-title":"Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma","volume":"19","author":"Shimizu","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R113-20250602","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R114-20250602","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"R115-20250602","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"R116-20250602","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R117-20250602","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"R118-20250602","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R119-20250602","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/hbsn-20-846","article-title":"Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen","volume":"10","author":"Cui","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R120-20250602","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12885-021-08549-2","article-title":"Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study","volume":"21","author":"Zou","year":"2021","journal-title":"BMC Cancer"},{"key":"R121-20250602","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","article-title":"Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"4","author":"Sahai","year":"2018","journal-title":"JAMA Oncol"},{"key":"R122-20250602","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R123-20250602","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R124-20250602","doi-asserted-by":"crossref","first-page":"12263","DOI":"10.1002\/cam4.5924","article-title":"Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"R125-20250602","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"R126-20250602","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"R127-20250602","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"R128-20250602","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/bjc.2014.343","article-title":"Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer","volume":"111","author":"Hezel","year":"2014","journal-title":"Br J Cancer"},{"key":"R129-20250602","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"R130-20250602","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"R131-20250602","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"R132-20250602","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaoncol.2020.6166","article-title":"Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)","volume":"7","author":"Ramaswamy","year":"2021","journal-title":"JAMA Oncol"},{"key":"R133-20250602","doi-asserted-by":"crossref","first-page":"100314","DOI":"10.1016\/j.esmoop.2021.100314","article-title":"Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)","volume":"7","author":"Javle","year":"2022","journal-title":"ESMO Open"},{"key":"R134-20250602","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"R135-20250602","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann Oncol"},{"key":"R136-20250602","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin","volume":"119","author":"Zheng","year":"2018","journal-title":"Br J Cancer"},{"key":"R137-20250602","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/cam4.3813","article-title":"A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy","volume":"10","author":"Ueno","year":"2021","journal-title":"Cancer Med"},{"key":"R138-20250602","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2020.01.026","article-title":"Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer","volume":"130","author":"Kim","year":"2020","journal-title":"Eur J Cancer"},{"key":"R139-20250602","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1002\/cncr.33803","article-title":"A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"R140-20250602","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"R141-20250602","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"R142-20250602","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"R143-20250602","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"R144-20250602","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R145-20250602","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R146-20250602","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2023.41.4_suppl.491","article-title":"IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer","volume":"41","author":"El-Khoueiry","year":"2023","journal-title":"J Clin Oncol"},{"key":"R147-20250602","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R148-20250602","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"R149-20250602","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"R150-20250602","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"R151-20250602","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"R152-20250602","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R153-20250602","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CM9.0000000000002759","article-title":"Advances in immunotherapy for biliary tract cancers","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin Med J"},{"key":"R154-20250602","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"R155-20250602","doi-asserted-by":"crossref","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R156-20250602","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"R157-20250602","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"R158-20250602","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"R159-20250602","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13014-020-01703-3","article-title":"Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group","volume":"15","author":"Parzen","year":"2020","journal-title":"Radiat Oncol"},{"key":"R160-20250602","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"key":"R161-20250602","doi-asserted-by":"crossref","first-page":"e051421","DOI":"10.1136\/bmjopen-2021-051421","article-title":"Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"BMJ Open"},{"key":"R162-20250602","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13014-020-1459-x","article-title":"A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"15","author":"Ren","year":"2020","journal-title":"Radiat Oncol"},{"key":"R163-20250602","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1245\/s10434-017-6139-1","article-title":"Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis","volume":"25","author":"Kim","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R164-20250602","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12072-022-10343-6","article-title":"Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis","volume":"16","author":"Choi","year":"2022","journal-title":"Hepatol Int"},{"key":"R165-20250602","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2011.05.003","article-title":"Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies","volume":"38","author":"Bonet Beltr\u00e1n","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"R166-20250602","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1631\/jzus.B1900691","article-title":"Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis","volume":"21","author":"Shi","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"key":"R167-20250602","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.dld.2020.08.030","article-title":"Italian Clinical Practice Guidelines on Cholangiocarcinoma-Part II: Treatment","volume":"52","year":"2020","journal-title":"Dig Liver Dis"},{"key":"R168-20250602","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.radonc.2017.09.025","article-title":"Nodal areas of potential geographic error in adjuvant radiotherapy for biliary tract cancer","volume":"125","author":"Socha","year":"2017","journal-title":"Radiother Oncol"},{"key":"R169-20250602","doi-asserted-by":"crossref","first-page":"955","DOI":"10.21873\/anticanres.11404","article-title":"Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies","volume":"37","author":"Marinelli","year":"2017","journal-title":"Anticancer Res"},{"key":"R170-20250602","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejso.2016.12.008","article-title":"A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer","volume":"43","author":"Kobayashi","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R171-20250602","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.3748\/wjg.v23.i18.3301","article-title":"Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma","volume":"23","author":"Jung","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R172-20250602","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/hpb.12150","article-title":"Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review","volume":"16","author":"Grendar","year":"2014","journal-title":"HPB (Oxford)"},{"key":"R173-20250602","doi-asserted-by":"crossref","first-page":"20170061","DOI":"10.1259\/bjr.20170061","article-title":"External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence","volume":"90","author":"Sahai","year":"2017","journal-title":"Br J Radiol"},{"key":"R174-20250602","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/CMAR.S160680","article-title":"Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching","volume":"10","author":"Shao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R175-20250602","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/PPO.0000000000000213","article-title":"Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma","volume":"22","author":"Jackson","year":"2016","journal-title":"Cancer J"},{"key":"R176-20250602","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1245\/s10434-017-6131-9","article-title":"Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis","volume":"24","author":"Torgeson","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R177-20250602","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.radonc.2018.09.010","article-title":"Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: Nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"R178-20250602","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/ijc.IJC_1145_20","article-title":"Consolidation chemoradiation (cCTRT) improves survival in responders to first-line chemotherapy (CT) in locally advanced gallbladder cancer (LA-GBC): A new standard of care?","volume":"59","author":"Alam","year":"2022","journal-title":"Indian J Cancer"},{"key":"R179-20250602","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/jcrt.JCRT_1568_20","article-title":"Radiotherapy for locally advanced unresectable gallbladder cancer - A way forward: Comparative study of chemotherapy versus chemoradiotherapy","volume":"18","author":"Sinha","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R180-20250602","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1748-717X-8-292","article-title":"Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma","volume":"8","author":"Kim","year":"2013","journal-title":"Radiat Oncol"},{"key":"R181-20250602","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/1471-2407-10-492","article-title":"Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients","volume":"10","author":"Chen","year":"2010","journal-title":"BMC Cancer"},{"key":"R182-20250602","first-page":"113","article-title":"Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients","volume":"12","author":"Zeng","year":"2006","journal-title":"Cancer J"},{"key":"R183-20250602","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","article-title":"Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a\u00a0meta-analysis and systematic review","volume":"195","author":"Lee","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"R184-20250602","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","author":"Brunner","year":"2019","journal-title":"Radiother Oncol"},{"key":"R185-20250602","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J Clin Oncol"},{"key":"R186-20250602","first-page":"737","article-title":"Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study","volume":"36","author":"Autorino","year":"2016","journal-title":"Anticancer Res"},{"key":"R187-20250602","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","article-title":"Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive 9902 phase II randomised study","volume":"50","author":"Phelip","year":"2014","journal-title":"European Journal of Cancer"},{"key":"R188-20250602","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1055\/a-0659-9864","article-title":"Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017","volume":"50","author":"Dumonceau","year":"2018","journal-title":"Endoscopy"},{"key":"R189-20250602","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s10147-021-01926-8","article-title":"Negative prognostic outcomes of percutaneous transhepatic biliary drainage in distal cholangiocarcinoma: a retrospective analysis using propensity score matching","volume":"26","author":"Matsunaga","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"R190-20250602","doi-asserted-by":"crossref","first-page":"E363","DOI":"10.1111\/ans.15329","article-title":"Impact of preoperative percutaneous transhepatic biliary drainage on post-operative survival in patients with distal cholangiocarcinoma","volume":"89","author":"Mori","year":"2019","journal-title":"ANZ J Surg"},{"key":"R191-20250602","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.amjsurg.2017.01.010","article-title":"Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma","volume":"214","author":"Miura","year":"2017","journal-title":"Am J Surg"},{"key":"R192-20250602","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00535-015-1140-6","article-title":"Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinoma","volume":"51","author":"Komaya","year":"2016","journal-title":"J Gastroenterol"},{"key":"R193-20250602","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2015.3670","article-title":"Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort","volume":"2","author":"Inamdar","year":"2016","journal-title":"JAMA Oncol"},{"key":"R194-20250602","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jgh.12128","article-title":"Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma","volume":"28","author":"Rerknimitr","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R195-20250602","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cgh.2020.05.035","article-title":"An Unsuccessful Randomized Trial of Percutaneous vs Endoscopic Drainage of Suspected Malignant Hilar Obstruction","volume":"19","author":"Elmunzer","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R196-20250602","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2468-1253(18)30234-6","article-title":"Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial","volume":"3","author":"Coelen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R197-20250602","doi-asserted-by":"crossref","first-page":"100163","DOI":"10.1016\/j.clinsp.2022.100163","article-title":"Endoscopic Biliary Darinage (EBD) versus Percutaneous Transhepatic Biliary Drainage (PTBD) for biliary drainage in patients with Perihilar Cholangiocarcinoma (PCCA): A systematic review and meta-analysis","volume":"78","author":"Moll","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"R198-20250602","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1553350620911291","article-title":"Endoscopic Versus Percutaneous Preoperative Biliary Drainage in Patients With Klatskin Tumor Undergoing Curative Surgery: A Systematic Review and Meta-Analysis of Short-Term and Long-Term Outcomes","volume":"27","author":"Hajibandeh","year":"2020","journal-title":"Surg Innov"},{"key":"R199-20250602","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12957-019-1656-y","article-title":"A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction","volume":"17","author":"Wang","year":"2019","journal-title":"World J Surg Oncol"},{"key":"R200-20250602","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gie.2020.12.016","article-title":"Endoscopic radiofrequency ablation plus plastic stent placement versus stent placement alone for unresectable extrahepatic biliary cancer: a multicenter randomized controlled trial","volume":"94","author":"Gao","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"R201-20250602","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1055\/s-0043-124870","article-title":"Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial","volume":"50","author":"Yang","year":"2018","journal-title":"Endoscopy"},{"key":"R202-20250602","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5946\/ce.2020.254","article-title":"Survival Benefit of Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction: A Systematic Review with Meta-Analysis","volume":"54","author":"Cha","year":"2021","journal-title":"Clin Endosc"},{"key":"R203-20250602","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3390\/cancers14092079","article-title":"Comparison of Intraductal RFA Plus Stent versus Stent-Only Treatment for Unresectable Perihilar Cholangiocarcinoma-A Systematic Review and Meta-Analysis","volume":"14","author":"de Jong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R204-20250602","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/MCG.0000000000001524","article-title":"Photodynamic Therapy (PDT), Radiofrequency Ablation (RFA) With Biliary Stents in Palliative Treatment of Unresectable Extrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis","volume":"56","author":"Mohan","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"R205-20250602","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4253\/wjge.v15.i3.177","article-title":"Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review","volume":"15","author":"Rebhun","year":"2023","journal-title":"World J Gastrointest Endosc"},{"key":"R206-20250602","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.gie.2017.10.029","article-title":"Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: a\u00a0systematic review and meta-analysis","volume":"87","author":"Sofi","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"R207-20250602","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1007\/s00464-022-09181-2","article-title":"Local palliative therapies for unresectable malignant biliary obstruction: radiofrequency ablation combined with stent or biliary stent alone? An updated meta-analysis of nineteen trials","volume":"36","author":"Song","year":"2022","journal-title":"Surg Endosc"},{"key":"R208-20250602","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/1751-2980.12429","article-title":"Endoscopic radiofrequency ablation may be preferable in the management of malignant biliary obstruction: A systematic review and meta-analysis","volume":"17","author":"Zheng","year":"2016","journal-title":"J Dig Dis"},{"key":"R209-20250602","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.pdpdt.2022.102712","article-title":"Benefits and safety of photodynamic therapy in patients with hilar cholangiocarcinoma: A meta-analysis","volume":"37","author":"Chen","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"R210-20250602","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00534-009-0109-3","article-title":"Systematic review: photodynamic therapy for unresectable cholangiocarcinoma","volume":"17","author":"Gao","year":"2010","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R211-20250602","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3748\/wjg.v23.i7.1278","article-title":"Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis","volume":"23","author":"Moole","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R212-20250602","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.gie.2022.05.022","article-title":"Impact of endobiliary radiofrequency ablation on biliary drainage in patients with malignant biliary strictures treated with uncovered self-expandable metal stents: a randomized controlled multicenter trial","volume":"96","author":"Albers","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"R213-20250602","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jhbp.1082","article-title":"Efficacy and safety of temperature-controlled intraductal radiofrequency ablation in advanced malignant hilar biliary obstruction: A pilot multicenter randomized comparative trial","volume":"29","author":"Kang","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R214-20250602","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/YYMN9802","article-title":"Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review","volume":"27","author":"Beyer","year":"2023","journal-title":"Health Technol Assess"},{"key":"R215-20250602","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.gastro.2003.07.015","article-title":"Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study","volume":"125","author":"Ortner","year":"2003","journal-title":"Gastroenterology"},{"key":"R216-20250602","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1572-0241.2005.00318.x","article-title":"Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy","volume":"100","author":"Zoepf","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R217-20250602","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0016-5107(03)70021-2","article-title":"Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma","volume":"57","author":"Dumoulin","year":"2003","journal-title":"Gastrointest Endosc"},{"key":"R218-20250602","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cgh.2007.12.004","article-title":"Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy","volume":"6","author":"Kahaleh","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R219-20250602","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1007\/s00464-020-08095-1","article-title":"Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma","volume":"35","author":"Li","year":"2021","journal-title":"Surg Endosc"},{"key":"R220-20250602","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.sla.0000217639.10331.47","article-title":"Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1\/r2 resection","volume":"244","author":"Witzigmann","year":"2006","journal-title":"Ann Surg"},{"key":"R221-20250602","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pdpdt.2016.10.001","article-title":"Treatment of unresectable extrahepatic cholangiocarcinoma using hematoporphyrin photodynamic therapy: A prospective study","volume":"16","author":"Yang","year":"2016","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"R222-20250602","doi-asserted-by":"crossref","first-page":"103318","DOI":"10.1016\/j.pdpdt.2023.103318","article-title":"Photodynamic therapy combined with systemic chemotherapy for unresectable extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"41","author":"Yu","year":"2023","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"R223-20250602","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"},{"key":"R224-20250602","doi-asserted-by":"crossref","first-page":"E695","DOI":"10.1001\/amajethics.2020.695","article-title":"Revisiting the WHO Analgesic Ladder for Surgical Management of Pain","volume":"22","author":"McGuire","year":"2020","journal-title":"AMA J Ethics"},{"key":"R225-20250602","first-page":"52","article-title":"Interventional therapies for the management of cancer pain","volume":"8","author":"Brogan","year":"2010","journal-title":"J Support Oncol"},{"key":"R226-20250602","doi-asserted-by":"crossref","first-page":"989","DOI":"10.47102\/annals-acadmedsg.V38N11p989","article-title":"The role of interventional therapies in cancer pain management","volume":"38","author":"Tay","year":"2009","journal-title":"Ann Acad Med Singap"},{"key":"R227-20250602","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2004.03.097","article-title":"Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study","volume":"22","author":"Goetz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R228-20250602","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2214\/AJR.09.2975","article-title":"Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma","volume":"194","author":"Kashima","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"R229-20250602","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/nu11051145","article-title":"The Effect of Nutrition Intervention with Oral Nutritional Supplements on Pancreatic and Bile Duct Cancer Patients Undergoing Chemotherapy","volume":"11","author":"Kim","year":"2019","journal-title":"Nutrients"},{"key":"R230-20250602","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-2000-14886","article-title":"Long-term outcome in patients with advanced hilar bile duct tumors undergoing palliative endoscopic or percutaneous drainage","volume":"38","author":"Born","year":"2000","journal-title":"Z Gastroenterol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:07:47Z","timestamp":1748876867000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":229,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003258","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"2024-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}